麦科医药-B(02335.HK) 公布,集团自主研发用于治疗急性缺血性脑卒中(AIS)的注射用神经保护候选药物MT200605的临床前及I期临床数据,获接纳于2026年第十八届世界卒中大会“WSC 2026”作口头报告。WSC 2026将于10月21日至23日在韩国首尔举行。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻
Source Link麦科医药-B(02335.HK) 公布,集团自主研发用于治疗急性缺血性脑卒中(AIS)的注射用神经保护候选药物MT200605的临床前及I期临床数据,获接纳于2026年第十八届世界卒中大会“WSC 2026”作口头报告。WSC 2026将于10月21日至23日在韩国首尔举行。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.